Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immunization plays a crucial role in protecting children from life-threatening conditions such as pneumococcal disease. Pneumococcal disease can affect multiple organ systems and manifest as an invasive or noninvasive disease. Despite being preventable by vaccines, it remains a public health concern in India. The development of pneumococcal conjugate vaccines (PCVs) has helped reduce the burden of pneumococcal disease by overcoming the limitations of polysaccharide vaccines, especially in young children. Although immunogenicity is used as a proxy for the evaluation and approval of PCVs, results from immunogenicity studies have been bridged back to vaccine trial efficacy. Post-approval effectiveness and impact of new PCVs must be established. This review aims to consolidate evidence-based considerations that play a role in the evaluation of PCVs. Critical aspects related to the assessment of vaccines, their importance, and limitations in real-world contexts are discussed in this review.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11980484 | PMC |
| http://dx.doi.org/10.1080/21645515.2025.2482285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Developing a Latin American Delphi consensus on vaccination for respiratory diseases in older adults.
Ann Geriatr Med Res
September 2025
Academia Latinoamericana de Medicina del Adulto Mayor - ALMA.
Background: Respiratory infections significantly impact older adults in Latin America, highlighting the need for regionally adapted consensus-based vaccination recommendations to guide preventive strategies. This study aimed to develop a consensus among Latin American experts on vaccination against respiratory diseases in older adults in the region, including influenza, Streptococcus pneumoniae pneumonia, COVID-19, respiratory syncytial virus (RSV), and pertussis.
Methods: A two-round Delphi methodology was employed, involving 35 specialists from various medical fields.
Pneumococcal colonization rates in children and adults in two developing countries: A prospective cross-sectional hospital-based study.
Vaccine
September 2025
Mérieux Foundation, 17 Rue Bourgelat, 69002 Lyon, France. Electronic address:
Introduction: Streptococcus pneumoniae is a major cause of lower respiratory infections, especially in children under 5 years old. While pneumococcal conjugate vaccines (PCVs) have reduced disease burden in many countries, data from low- and middle-income countries are still limited. The objective of this prospective, hospital-based, cross -sectional study was to measure the prevalence of pneumococcal colonization and identify circulating serotypes among children <5 years and their caregivers in Cambodia and India.
View Article and Find Full Text PDFOverview: We analysed Australian Immunisation Register (AIR) data, predominantly for National Immunisation Program funded vaccines, as at 2 April 2023 for children, adolescents and adults, focusing on the calendar year 2022 and on trends from previous years. This report aims to provide comprehensive analysis and interpretation of vaccination coverage data to inform immunisation policy and programs.
Children: Fully vaccinated coverage in Australian children in 2022 was 0.
Genomic analysis of the in Taiwan: a nationwide study from 2006 to 2022.
Microb Genom
September 2025
National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan, ROC.
remains a leading respiratory pathogen for children and the elderly. In Taiwan, a national PCV13 catch-up vaccination programme for children began in March 2013. This study investigates the population structure and antimicrobial profiles of pneumococcal isolates in Taiwan from 2006 to 2022.
View Article and Find Full Text PDFVaccine Immunity Against Pneumococcus in Children With Sickle Cell Disease: A Retrospective Single-center Study.
Pediatr Infect Dis J
September 2025
Division of General Pediatrics, Department of Pediatrics, Gynecology and Obstetrics, Unit of Immunology, Vaccinology, and Rheumatology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Background And Aims: Sickle cell disease (SCD) patients are at a higher risk of pneumococcal invasive diseases. Vaccination is the central strategy for protecting these children, along with penicillin prophylaxis. However, it is unclear how often these children should be revaccinated with pneumococcal vaccines.
View Article and Find Full Text PDF